Athersys (ATHX) Shares Up 9.4%

Athersys, Inc. (NASDAQ:ATHX) shares shot up 9.4% during mid-day trading on Friday . The stock traded as high as $1.64 and last traded at $1.63. 646,521 shares traded hands during trading, an increase of 10% from the average session volume of 589,025 shares. The stock had previously closed at $1.49.

Separately, Zacks Investment Research downgraded shares of Athersys from a “buy” rating to a “hold” rating in a report on Monday, February 18th.

Get Athersys alerts:

The firm has a market capitalization of $211.20 million, a PE ratio of -5.62 and a beta of 0.50.

In other news, insider William Lehmann, Jr. sold 15,000 shares of the business’s stock in a transaction dated Tuesday, December 18th. The shares were sold at an average price of $1.73, for a total transaction of $25,950.00. Following the transaction, the insider now owns 493,062 shares in the company, valued at approximately $852,997.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 18.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Athersys by 11.6% in the fourth quarter. BlackRock Inc. now owns 7,555,866 shares of the biopharmaceutical company’s stock valued at $10,881,000 after acquiring an additional 786,445 shares during the period. Vanguard Group Inc increased its stake in Athersys by 2.4% in the third quarter. Vanguard Group Inc now owns 5,707,784 shares of the biopharmaceutical company’s stock valued at $11,986,000 after acquiring an additional 134,541 shares during the period. Vanguard Group Inc. increased its stake in Athersys by 2.4% in the third quarter. Vanguard Group Inc. now owns 5,707,784 shares of the biopharmaceutical company’s stock valued at $11,986,000 after acquiring an additional 134,541 shares during the period. Geode Capital Management LLC increased its stake in Athersys by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 1,386,956 shares of the biopharmaceutical company’s stock valued at $1,997,000 after acquiring an additional 61,106 shares during the period. Finally, TIAA CREF Investment Management LLC increased its stake in Athersys by 61.7% in the third quarter. TIAA CREF Investment Management LLC now owns 461,736 shares of the biopharmaceutical company’s stock valued at $970,000 after acquiring an additional 176,218 shares during the period. 20.29% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4188953/athersys-athx-shares-up-9-4.html.

Athersys Company Profile (NASDAQ:ATHX)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Recommended Story: Beta